Abstract
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a common occurrence and characterize the natural history of the disease. Over the past decade, new knowledge has substantially enhanced our understanding of the pathogenesis, outcome and natural history of AECOPD. The exacerbations not only greatly reduce the quality of life of these patients, but also result in hospitalization, respiratory failure, and death. The exacerbations are the major cost drivers in consumption of healthcare resources by COPD patients. Although bacterial infections are the most common etiologic agents, the role of viruses in COPD exacerbations is being increasingly recognized. The efficacy of antimicrobial therapy in acute exacerbations has established a causative role for bacterial infections. Recent molecular typing of sputum isolates further supports the role of bacteria in AECOPD. Isolation of a new strain of Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae was associated with a considerable risk of an exacerbation. Lower airway bacterial colonization in stable patients with COPD instigates airway inflammation, which leads to a protracted self-perpetuating vicious circle of progressive lung damage and disease progression. A significant proportion of patients treated for COPD exacerbation demonstrate incomplete recovery, and frequent exacerbations contribute to decline in lung function. The predictors of poor outcome include advanced age, significant impairment of lung function, poor performance status, comorbid conditions and history of previous frequent exacerbations requiring antibacterials or systemic corticosteroids. These high-risk patients, who are likely to harbor organisms resistant to commonly used antimicrobials, should be identified and treated with antimicrobials with a low potential for failure. An aggressive management approach in complicated exacerbations may reduce costs by reducing healthcare utilization and hospitalization.
Keywords: Chronic Obstructive Pulmonary Disease, Clarithromycin, Chronic Obstructive Pulmonary Disease Patient, Azithromycin, Acute Exacerbation
References
- 1.Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76. doi: 10.1164/ajrccm.163.5.2101039. [DOI] [PubMed] [Google Scholar]
- 2.National Heart, LungBlood Institute . Morbidity & mortality: Chartbook on cardiovascular, lung and blood diseases. Bethesda (MD): US Department of Health and Human Services, Public Health Service, National Institute of Health; 1998. [Google Scholar]
- 3.Statistical abstract of the United States, 2004. Washington Census Bureau 2004: 103: 24. Available from URL: http://www.census.gov/prod/www/statistical-abstract-04.html [Accessed 2005 Apr 30]
- 4.Murray CJL, Lopez AD. Evidence-based health policy lessons from the Global Burden of Disease Study. Science. 1996;274:740–3. doi: 10.1126/science.274.5288.740. [DOI] [PubMed] [Google Scholar]
- 5.The COPD Guidelines Group of the Standards of Care Committee of the BTS BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax. 1997;52(5):S1–S28. [PMC free article] [PubMed] [Google Scholar]
- 6.Connors AF, Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease [published erratum appears in Am J Respir Crit Care Med 1997; 155: 386] Am J Respir Crit Care Med. 1996;154:959–67. doi: 10.1164/ajrccm.154.4.8887592. [DOI] [PubMed] [Google Scholar]
- 7.Voelkel NF, Tuder R. COPD Exacerbation. Chest. 2000;117:376S–9S. doi: 10.1378/chest.117.5_suppl_2.376S. [DOI] [PubMed] [Google Scholar]
- 8.Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
- 9.Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(2):398S–401S. doi: 10.1378/chest.117.5_suppl_2.398S. [DOI] [PubMed] [Google Scholar]
- 10.McHardy VU, Inglis JM, Calder MA, et al. A study of infective and other factors in exacerbations of chronic bronchitis. Br J Dis Chest. 1980;74:228–38. doi: 10.1016/0007-0971(80)90048-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med. 1998;157:1498–505. doi: 10.1164/ajrccm.157.5.9711044. [DOI] [PubMed] [Google Scholar]
- 12.Wedzidha JA. Exacerbations, etiology and pathophysiologic mechanics. Chest. 2002;121:1365–415. doi: 10.1378/chest.121.4.1365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 200: a state-of-the-art review. Clin Microbiol Rev. 2001;14:336–63. doi: 10.1128/CMR.14.2.336-363.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Seemungal TAR, Wedzicha JA. Viral infections in obstructive airway diseases. Curr Opin Pulm Med. 2003;9:111–6. doi: 10.1097/00063198-200303000-00004. [DOI] [PubMed] [Google Scholar]
- 15.Smith CB, Golden C, Kenner R, et al. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1980;121:225–32. doi: 10.1164/arrd.1980.121.2.225. [DOI] [PubMed] [Google Scholar]
- 16.Fagon J-Y, Chastre J, Trouillet J-L, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis. 1990;142:1004–8. doi: 10.1164/ajrccm/142.5.1004. [DOI] [PubMed] [Google Scholar]
- 17.Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995;152:1316–20. doi: 10.1164/ajrccm.152.4.7551388. [DOI] [PubMed] [Google Scholar]
- 18.Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113(6):1542–8. doi: 10.1378/chest.113.6.1542. [DOI] [PubMed] [Google Scholar]
- 19.Hirschmann JV. Bacteria and COPD exacerbation redux. Chest. 2001;119:663–7. doi: 10.1378/chest.119.2.663. [DOI] [PubMed] [Google Scholar]
- 20.Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618–23. doi: 10.1164/ajrccm.164.9.2105011. [DOI] [PubMed] [Google Scholar]
- 21.Rhode G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization: a case control study. Thorax. 2003;58:37–42. doi: 10.1136/thorax.58.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hirschmann JV. Do bacteria cause exacerbations of COPD? Chest. 2000;118:193–203. doi: 10.1378/chest.118.1.193. [DOI] [PubMed] [Google Scholar]
- 23.Tager I, Speizer FE. Role of infection in chronic bronchitis. N Engl J Med. 1975;292:563–71. doi: 10.1056/NEJM197503132921105. [DOI] [PubMed] [Google Scholar]
- 24.Murphy TF, Sethi S. State of the art; bacterial infection in chronic obstructive lung disease. Am Rev Respir Dis. 1992;146:1067–83. doi: 10.1164/ajrccm/146.4.1067. [DOI] [PubMed] [Google Scholar]
- 25.Patel IS, Seemungal TAR, Wilks M, et al. Relationship between bacterial colonization and the frequency, character, and severity of COPD exacerbations. Thorax. 2002;57:759–64. doi: 10.1136/thorax.57.9.759. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Reichek N, Lewin EB, Rhoden DL, et al. Antibody responses to bacterial antigens during exacerbations of chronic bronchitis. Am Rev Respir Dis. 1970;101:238–44. doi: 10.1164/arrd.1970.101.2.238. [DOI] [PubMed] [Google Scholar]
- 27.Haase EM, Campagnari AA, Sarvar J, et al. Strain-specific and immunodominant surface epitopes of the P2 porin protein of non-typeable Haemophilus influenzae. Infect Immun. 1991;59:1278–84. doi: 10.1128/iai.59.4.1278-1284.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Medici TC, Chodosh S. The reticuloendothelial system in chronic bronchitis. Am Rev Respir Dis. 1972;105(5):792–804. doi: 10.1164/arrd.1972.105.5.792. [DOI] [PubMed] [Google Scholar]
- 29.Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000;109:288–95. doi: 10.1016/S0002-9343(00)00507-6. [DOI] [PubMed] [Google Scholar]
- 30.Stockley RA. Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax. 1998;53:58–62. doi: 10.1136/thx.53.1.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Stockley RA, O’Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638–45. doi: 10.1378/chest.117.6.1638. [DOI] [PubMed] [Google Scholar]
- 32.Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465–71. doi: 10.1056/NEJMoa012561. [DOI] [PubMed] [Google Scholar]
- 33.Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;117(2):380S–5S. doi: 10.1378/chest.117.5_suppl_2.380S. [DOI] [PubMed] [Google Scholar]
- 34.Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA. 1995;273:957–60. doi: 10.1001/jama.1995.03520360071042. [DOI] [PubMed] [Google Scholar]
- 35.Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. Ann Intern Med. 1982;97:18–21. doi: 10.7326/0003-4819-97-1-18. [DOI] [PubMed] [Google Scholar]
- 36.McCrory DC, Brown C, Gelfand SE, et al. Management of exacerbations of COPD: a summary and appraisal of the published evidence. Chest. 2001;119:1190–209. doi: 10.1378/chest.119.4.1190. [DOI] [PubMed] [Google Scholar]
- 37.Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest. 1999;16:40–6. doi: 10.1378/chest.116.1.40. [DOI] [PubMed] [Google Scholar]
- 38.Wilkinson TMA, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1090–5. doi: 10.1164/rccm.200210-1179OC. [DOI] [PubMed] [Google Scholar]
- 39.Stockley RA, Bayley D, Hill SL, et al. Assessment of airway neutrophils by sputum colour: correlation with airways inflammation. Thorax. 2001;56:366–72. doi: 10.1136/thorax.56.5.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Wedzicha JA. Airway infection accelerates decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(10):1757–8. doi: 10.1164/ajrccm.164.10.2108049a. [DOI] [PubMed] [Google Scholar]
- 41.Cole P, Wilson R. Host-microbial interrelationships in respiratory infection. Chest. 1989;95:217S–21S. doi: 10.1378/chest.95.3_Supplement.217S. [DOI] [Google Scholar]
- 42.Wilson R. Outcome predictors in bronchitis. Chest. 1995;108:53S–7S. doi: 10.1378/chest.108.2_Supplement.53S. [DOI] [PubMed] [Google Scholar]
- 43.Fletcher CM. Chronic bronchitis. Am Rev Respir Dis. 1959;80:483–94. doi: 10.1164/arrd.1959.80.4P1.483. [DOI] [PubMed] [Google Scholar]
- 44.Howard P. A long-term follow-up of respiratory symptoms and ventilatory function in a group of working men. Br J Ind Med. 1970;27:326–33. doi: 10.1136/oem.27.4.326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Bates DV. The fate of the chronic bronchitis: a report of the 10-year follow-up in the Canadian Department of Veterans Affairs coordinated study of chronic bronchitis. Am Rev Respir Dis. 1973;108:1043–65. doi: 10.1164/arrd.1973.108.5.1043. [DOI] [PubMed] [Google Scholar]
- 46.Anthonisen NR, Connett JE, Kiley J, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV 1. JAMA. 1994;272:1497–505. doi: 10.1001/jama.1994.03520190043033. [DOI] [PubMed] [Google Scholar]
- 47.Kanner RE, Anthonisen NR, Connett JE, et al. Lower respiratory illnesses promote FEV1 decline in current smokers but not in ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:358–64. doi: 10.1164/ajrccm.164.3.2010017. [DOI] [PubMed] [Google Scholar]
- 48.Seemungal TAR, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–13. doi: 10.1164/ajrccm.161.5.9908022. [DOI] [PubMed] [Google Scholar]
- 49.Spencer S, Jones PW, GLOBE Study Group Time course of recovery of health status following an ineffective exacerbation of chronic bronchitis. Thorax. 2003;58:589–93. doi: 10.1136/thorax.58.7.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Asmundsson T, Kilburn KH. Survival of acute respiratory failure: a study of 239 episodes. Ann Intern Med. 1969;70:471–89. doi: 10.7326/0003-4819-70-3-471. [DOI] [PubMed] [Google Scholar]
- 51.Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med. 1996;154:959–67. doi: 10.1164/ajrccm.154.4.8887592. [DOI] [PubMed] [Google Scholar]
- 52.Ball P, Harris JM, Lowson D, et al. Acute infective exacerbations of chronic bronchitis. QJM. 1995;88:61–8. [PubMed] [Google Scholar]
- 53.Dewan NA, Rafique S, Kanwar B, et al. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest. 2000;117(3):662–71. doi: 10.1378/chest.117.3.662. [DOI] [PubMed] [Google Scholar]
- 54.Roberts CM, Lowe D, Bucknall CE, et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax. 2002;57(2):137–41. doi: 10.1136/thorax.57.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Strom K. Survival of patients with chronic obstructive pulmonary disease receiving long-term domiciliary oxygen therapy. Am Rev Respir Dis. 1993;147:585–91. doi: 10.1164/ajrccm/147.3.585. [DOI] [PubMed] [Google Scholar]
- 56.Derenne JP, Fleury B, Pariente R. Acute respiratory failure of chronic obstructive lung disease. Am Rev Respir Dis. 1988;138:1006–33. doi: 10.1164/ajrccm/138.4.1006. [DOI] [PubMed] [Google Scholar]
- 57.Jansson SA, Andersson F, Borg S, et al. Costs of COPD in Sweden according to disease severity. Chest. 2002;122:1994–2002. doi: 10.1378/chest.122.6.1994. [DOI] [PubMed] [Google Scholar]
- 58.Hilleman DE, Dewan M, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest. 2000;118:1278–82. doi: 10.1378/chest.118.5.1278. [DOI] [PubMed] [Google Scholar]
- 59.Gibson PG, Wlodarczyk JH, Wilson AJ, et al. Severe exacerbations of chronic obstructive airways disease: health resource use in general practice and hospital. J Quai Clin Pract. 1998;18:125–33. [PubMed] [Google Scholar]
- 60.Miravitlles M, Murio C, Guerrero T, et al. Pharmacoeconomic evaluation of acute exacerbation of chronic bronchitis. Chest. 2002;121:1449–55. doi: 10.1378/chest.121.5.1449. [DOI] [PubMed] [Google Scholar]
- 61.Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117:5S–9S. doi: 10.1378/chest.117.2_suppl.5S. [DOI] [PubMed] [Google Scholar]
- 62.Rutten-van Molken MPMH, Postma MJ, Joore MA, et al. Current and future medical costs of asthma and chronic obstructive pulmonary disease in the Netherlands. Respir Med. 1999;93:779–87. doi: 10.1016/S0954-6111(99)90262-7. [DOI] [PubMed] [Google Scholar]
- 63.McGuire A, Irwin DE, Fenn P, et al. The excess of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health. 2001;4:370–5. doi: 10.1046/j.1524-4733.2001.45049.x. [DOI] [PubMed] [Google Scholar]
- 64.Pechevis M, Fagnani F, Brin S, et al. Infections respiratories récidivantes du sujet atteint de bronchite chronique obstructive: prise en charge médicale et coüts (Recurrent respiratory infections in patients with chronic obstructive bronchitis: medical management and costs) Rev Mal Respir. 1996;13:507–12. [PubMed] [Google Scholar]
- 65.Anderson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med. 2002;96(9):700–8. doi: 10.1053/rmed.2002.1334. [DOI] [PubMed] [Google Scholar]
- 66.Destache CJ, Dewan NA, O’Donohue WJ, et al. Clinical and economic considerations in acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;43(A):107–13. doi: 10.1093/jac/43.suppl_1.107. [DOI] [PubMed] [Google Scholar]
- 67.Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics. 1999;16:499–520. doi: 10.2165/00019053-199916050-00007. [DOI] [PubMed] [Google Scholar]
- 68.Quenzer RW, Pettit KG, Arnold RJ, et al. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection. Am J Manag Care. 1997;3:1027–36. [PubMed] [Google Scholar]
- 69.Backhouse R, Shakespeare A, Hutton J. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis. Br J Med Econ. 1995;8:11–25. [Google Scholar]
- 70.Saint S, Flaherty KR, Abrahamse P, et al. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin Ther. 2001;23(3):499–512. doi: 10.1016/S0149-2918(01)80053-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Van Barlingen H, Nuijten M, Volmer T, et al. Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany. J Med Econ. 1998;1:201–18. doi: 10.3111/199801201218. [DOI] [Google Scholar]
- 72.Anzueto A, Rizzo JA, Grossman RF. The infection free interval: its use in evaluating antimicrobial treatment of acute exacerbations of chronic bronchitis. Clin Infect Dis. 1999;91:87. doi: 10.1086/517802. [DOI] [PubMed] [Google Scholar]
- 73.Wool C, Cerutti R, Garbagna N, et al. A cost-effectiveness study of four different antibiotics in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Br J Med Econ. 1996;10:159–68. [Google Scholar]
- 74.MacFarlane JT, Colville A, Guion A, et al. Prospective study of etiology and outcome of adult lower respiratory tract infections in the community. Lancet. 1993;341:511–4. doi: 10.1016/0140-6736(93)90275-L. [DOI] [PubMed] [Google Scholar]
- 75.Lode H. Respiratory tract infections: when is antibiotic therapy indicated? Clin Ther. 1991;13:149–56. [PubMed] [Google Scholar]
- 76.Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:158–64. doi: 10.1164/ajrccm.159.1.9803117. [DOI] [PubMed] [Google Scholar]
- 77.Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67:495–501. doi: 10.1159/000067462. [DOI] [PubMed] [Google Scholar]
- 78.Miravitlles M, Murio C, Guerrero T, et al. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:928–33. doi: 10.1183/09031936.01.17509280. [DOI] [PubMed] [Google Scholar]
- 79.Balter MS, Hyland RH, Low DE, et al. Recommendations on the management of chronic bronchitis. CMAJ. 1994;10:5–23. [Google Scholar]
- 80.Balter MS, Forge JL, Low DE, et al. Canadian guideline for the management of acute exacerbation of chronic bronchitis: executive summary. Can Respir J. 2003;10:248–63. doi: 10.1155/2003/108656. [DOI] [PubMed] [Google Scholar]
- 81.Grossman RF. Guidelines for the treatment of acute exacerbation of chronic bronchitis. Chest 1997; Suppl. 112: 310S-3S [DOI] [PubMed]
- 82.Sharma S, Anthonisen N, et al. Antibiotics. In: Barnes P, Drazen J, Rennard S, et al., editors. Asthma and COPD: basic mechanisms and clinical management. London: Academic Press; 2002. pp. 573–86. [Google Scholar]
- 83.Sharma S, Anthonisen N. Antibiotics in AECOPD: acute exacerbation of chronic obstructive pulmonary disease. In: Siafakas N, New York (NY): Marcel Dekker Inc., editor. Lung Biol in Health Dis. 2003;183:331–4. [Google Scholar]
- 84.Adams SG, Jairo Melo J, Michael LM. Antibiotics are associated with lower relapse rate in outpatients with acute exacerbations iof COPD. Chest. 2000;117:1345–52. doi: 10.1378/chest.117.5.1345. [DOI] [PubMed] [Google Scholar]
- 85.Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother. 1997;41(2):292–7. doi: 10.1128/aac.41.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Doern GV, Brueggemann AB, Huynh H, et al. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-8. Emerg Infect Dis. 1999;5:757–65. doi: 10.3201/eid0506.990603. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Doern GV, Pfaller MA, Kugler K, et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from SENTRY antimicrobial surveillance program. Clin Infect Dis. 1999;27:764–70. doi: 10.1086/514953. [DOI] [PubMed] [Google Scholar]
- 88.Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother. 2001;45:1721–9. doi: 10.1128/AAC.45.6.1721-1729.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2003;46(4):285–9. doi: 10.1016/S0732-8893(03)00087-7. [DOI] [PubMed] [Google Scholar]
- 90.Jones ME, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000–2001. Clin Microbiol Infect. 2003;9(7):590–9. doi: 10.1046/j.1469-0691.2003.00573.x. [DOI] [PubMed] [Google Scholar]
- 91.Schito AM, Schito GC, Debbia E, et al. Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999–2000. J Chemother. 2003;15(3):226–34. doi: 10.1179/joc.2003.15.3.226. [DOI] [PubMed] [Google Scholar]
- 92.Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 1997;24(2):211–5. doi: 10.1093/clinids/24.2.211. [DOI] [PubMed] [Google Scholar]
- 93.Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;44:501–13. doi: 10.1093/jac/44.4.501. [DOI] [PubMed] [Google Scholar]
- 94.Gotfried MH, DeAbate CA, Fogarty C, et al. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther. 2001;23:97–107. doi: 10.1016/S0149-2918(01)80033-3. [DOI] [PubMed] [Google Scholar]
- 95.DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D. The safety and efficacy of short course moxifloxacin vs azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir Med. 2000;94:1029–37. doi: 10.1053/rmed.2000.0927. [DOI] [PubMed] [Google Scholar]
- 96.Grossman R, Mukharjee J, Vaughan D, et al. A one year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. The Canadian Ciprofloxacin Health Economic Study Group. Chest. 1998;113:131–41. doi: 10.1378/chest.113.1.131. [DOI] [PubMed] [Google Scholar]
- 97.Madaras-Kelly KJ, Magdanz SB, Johnson CK, et al. Clinical outcomes of ambulatory acute exacerbations of chronic bronchitis with older versus newer antimicrobials. Ann Pharmacother. 2002;36:975–80. doi: 10.1345/aph.1A315. [DOI] [PubMed] [Google Scholar]
- 98.Anzueto A. Treatment of acute exacerbations of chronic bronchitis: antibiotic therapy. Sem Resp Crit Care Med. 2000;21:97–106. doi: 10.1055/s-2000-9843. [DOI] [PubMed] [Google Scholar]
- 99.Thornsberry C, Ogilvie, Kahn J, et al. Surveillance of antimicrobial resistance in S pneumonia, H influenzae and M Catarrhalis in the United States in 1996–1997. Diagn Microbiol Infect Dis. 1997;29:249–57. doi: 10.1016/S0732-8893(97)00195-8. [DOI] [PubMed] [Google Scholar]
- 100.Maesen FPV, Geraedts WH, Davies BI. Cefaclor in the treatment of chronic bronchitis. J Antimicrob Chemother. 1990;26:456–8. doi: 10.1093/jac/26.3.456. [DOI] [PubMed] [Google Scholar]
- 101.Verghese A. Efficacy of cefixime in respiratory tract infections. Adv Ther. 1990;7:9–15. [Google Scholar]
- 102.White AR, Kaye C, Poupard J, et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004;53(1):3–20. doi: 10.1093/jac/dkh050. [DOI] [PubMed] [Google Scholar]
- 103.Todd PA, Benfield P. Amoxicillin/clavulanic: an update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1990;39:264–307. doi: 10.2165/00003495-199039020-00008. [DOI] [PubMed] [Google Scholar]
- 104.Mehta S, Parr JH, Morgan DJR. A comparison of cefuroxime and co-trimoxazole in severe respiratory tract infections. J Antimicrob Chemother. 1982;9:479–84. doi: 10.1093/jac/9.6.479. [DOI] [PubMed] [Google Scholar]
- 105.Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Infect Dis. 2001;32(11):1608–14. doi: 10.1086/320532. [DOI] [PubMed] [Google Scholar]
- 106.Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin resistant and multidrug resistant Streptococcus pneumonia: a multicentre study. Clin Infect Dis. 1997;24:1052–9. doi: 10.1086/513628. [DOI] [PubMed] [Google Scholar]
- 107.Zhanel GG, Dueck M, Hoban DJ, et al. Review of macrolides and ketolides: fcus on respiratory tract infections. Drugs. 2001;61:443–98. doi: 10.2165/00003495-200161040-00003. [DOI] [PubMed] [Google Scholar]
- 108.Hoepelma IM, Mollers MJ, vanSchie MH, et al. A short (3 day) course of azithromycin tablet versus a 10-day course of amoxicillin-clavulanic acid in the treatment of adults with lower respiratory tract infections and effects on long term outcome. Int J Antimicrob Agents. 1997;9:141–6. doi: 10.1016/S0924-8579(97)00043-5. [DOI] [PubMed] [Google Scholar]
- 109.Alvarez-Elcoro S, Eichel B, Ellis C, et al. Erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc. 1999;74:613–34. doi: 10.4065/74.6.613. [DOI] [PubMed] [Google Scholar]
- 110.Amsden GW, Baird IM, Simon S, et al. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest. 2003;123:772–7. doi: 10.1378/chest.123.3.772. [DOI] [PubMed] [Google Scholar]
- 111.Castaldo RS, Celli BR, Gomez F, et al. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Ther. 2003;25:542–57. doi: 10.1016/S0149-2918(03)80095-4. [DOI] [PubMed] [Google Scholar]
- 112.Weiss K, Vanjaka A, Canadian Clarithromycin Study Group on Bronchitis An open-label, randomized, multicentre, comparative study of the efficacy and safety of 7 days of treatment with clarithromycin extended release tablets versus clarithromycin immediate-release tablets for the treatment of patients with acute bacterial exacerbation of chronic bronchitis. Clin Ther. 2002;24:2105–22. doi: 10.1016/S0149-2918(02)80100-X. [DOI] [PubMed] [Google Scholar]
- 113.Bachand RT. A comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother. 1991;27(A):91–100. doi: 10.1093/jac/27.suppl_a.91. [DOI] [PubMed] [Google Scholar]
- 114.Anzueto A, Fisher CL, Jr, Busman T, et al. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin Ther. 2001;23(1):72–86. doi: 10.1016/S0149-2918(01)80031-X. [DOI] [PubMed] [Google Scholar]
- 115.Martinot JB, Carr WD, Cullen S, et al. Clarithromycin Once-a-Day Study Group. A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv Ther. 2001;18:1–11. doi: 10.1007/BF02850246. [DOI] [PubMed] [Google Scholar]
- 116.Blondeau JM. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new “respiratory quinolones”. J Antimicrob Chemother. 1999;43(B):1–11. doi: 10.1093/jac/43.suppl_2.1. [DOI] [PubMed] [Google Scholar]
- 117.Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J Antimicrob Chemother. 2002;50(1):151–4. doi: 10.1093/jac/dkf133. [DOI] [PubMed] [Google Scholar]
- 118.Bishai W. Current issues on resistance, treatment guidelines, and the appropriate use of fluoroquinolones for respiratory tract infections. Clin Ther. 2002;24(6):838–50. doi: 10.1016/S0149-2918(02)80002-9. [DOI] [PubMed] [Google Scholar]
- 119.Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750mg b.i.d. versus clarithromycin 500mg b.i.d. Bronchitis Study Group. Clin Ther. 1998;20(5):885–900. doi: 10.1016/s0149-2918(98)80071-4. [DOI] [PubMed] [Google Scholar]
- 120.Shah PM, Maesen FP, Dolmann A, et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother. 1999;43:529–39. doi: 10.1093/jac/43.4.529. [DOI] [PubMed] [Google Scholar]
- 121.Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbations of chronic bronchitis. Int J Antimicrob Agents. 2001;18:503–12. doi: 10.1016/S0924-8579(01)00435-6. [DOI] [PubMed] [Google Scholar]
- 122.Gotfried MH, DeAbate CA, Fogarty C, et al. Comparison of 5-day, short cause gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther. 2001;23:97–107. doi: 10.1016/S0149-2918(01)80033-3. [DOI] [PubMed] [Google Scholar]
- 123.Anzueto A, Gotfried M, Wilder MA, et al. Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis. Clin Ther 2002, 17 [DOI] [PubMed]
- 124.Chodosh S, DeAbate CA, Haverstock D, et al. Short course of moxifloxacin therapy for treatment of acute exacerbation of chronic bronchitis. Respir Med. 2000;94:18–27. doi: 10.1053/rmed.1999.0708. [DOI] [PubMed] [Google Scholar]
- 125.Schaberg T, Ballin I, Huchon G, et al. A Multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res. 2001;29:314–28. doi: 10.1177/147323000102900408. [DOI] [PubMed] [Google Scholar]
- 126.Grassi C, Casali L, Curti E, et al. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB) J Chemother. 2002;14:597–608. doi: 10.1179/joc.2002.14.6.597. [DOI] [PubMed] [Google Scholar]
- 127.Wilson R, Allegra L, Huchon G, et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest. 2004;125:953–64. doi: 10.1378/chest.125.3.953. [DOI] [PubMed] [Google Scholar]
- 128.Wilson R, Schentag JJ, Ball P, et al. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther. 2002;24:639–52. doi: 10.1016/S0149-2918(02)85139-6. [DOI] [PubMed] [Google Scholar]
- 129.Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58(7):589–93. doi: 10.1136/thorax.58.7.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
